Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials

British Journal of Cancer, Published online: 31 January 2020; doi:10.1038/s41416-020-0733-xPredictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trials

Source: British Journal of Cancer - January 30, 2020 Category: Cancer & Oncology Authors: Florence Lerebours Marina Pulido Emmanuelle Fourme Marc Debled V éronique Becette Herv é Bonnefoi Sofia Rivera Gaetan MacGrogan Marie-Ange Mouret-Reynier Christine Tunon de Lara Jean-Yves Pierga Christel Breton-Callu Laurence Venat-Bouvet Simone Mathoul Source Type: research